RU2020114890A - Кристаллическое промежуточное соединение, используемое для получения линаглиптина, и способ получения линаглиптина - Google Patents
Кристаллическое промежуточное соединение, используемое для получения линаглиптина, и способ получения линаглиптина Download PDFInfo
- Publication number
- RU2020114890A RU2020114890A RU2020114890A RU2020114890A RU2020114890A RU 2020114890 A RU2020114890 A RU 2020114890A RU 2020114890 A RU2020114890 A RU 2020114890A RU 2020114890 A RU2020114890 A RU 2020114890A RU 2020114890 A RU2020114890 A RU 2020114890A
- Authority
- RU
- Russia
- Prior art keywords
- linagliptin
- formula
- crystalline form
- intermediate compound
- prepare
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741034292 | 2017-09-27 | ||
| IN201741034292 | 2017-09-27 | ||
| PCT/IB2018/057484 WO2019064214A1 (en) | 2017-09-27 | 2018-09-27 | INTERMEDIATE OF CRYSTALLINE LINAGLIPTIN AND PROCESS FOR THE PREPARATION OF LINAGLIPTIN |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020114890A true RU2020114890A (ru) | 2021-10-27 |
| RU2020114890A3 RU2020114890A3 (cg-RX-API-DMAC7.html) | 2022-08-10 |
Family
ID=65903063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020114890A RU2020114890A (ru) | 2017-09-27 | 2018-09-27 | Кристаллическое промежуточное соединение, используемое для получения линаглиптина, и способ получения линаглиптина |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11040974B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020535193A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200092946A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111511743A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018343236A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020005964A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3076980A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020004050A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2020114890A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019064214A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110684026A (zh) * | 2019-10-24 | 2020-01-14 | 扬子江药业集团上海海尼药业有限公司 | 一种利格列汀的工业化制备方法 |
| CN110872292B (zh) * | 2019-11-30 | 2022-01-25 | 江苏君若药业有限公司 | 一条合成糖尿病药物利拉利汀的路线 |
| EP4349837A1 (en) | 2022-10-05 | 2024-04-10 | Zaklady Farmaceutyczne "Polpharma" S.A. | A pharmaceutical intermediate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| IN2013MU02055A (cg-RX-API-DMAC7.html) * | 2013-06-18 | 2015-07-03 | Cadila Healthcare Ltd | |
| WO2015011609A1 (en) * | 2013-07-23 | 2015-01-29 | Ranbaxy Laboratories Limited | Process for the preparation of linagliptin and an intermediate thereof |
-
2018
- 2018-09-27 CA CA3076980A patent/CA3076980A1/en active Pending
- 2018-09-27 MX MX2020004050A patent/MX2020004050A/es unknown
- 2018-09-27 KR KR1020207012196A patent/KR20200092946A/ko not_active Ceased
- 2018-09-27 JP JP2020517938A patent/JP2020535193A/ja active Pending
- 2018-09-27 WO PCT/IB2018/057484 patent/WO2019064214A1/en not_active Ceased
- 2018-09-27 RU RU2020114890A patent/RU2020114890A/ru unknown
- 2018-09-27 AU AU2018343236A patent/AU2018343236A1/en not_active Abandoned
- 2018-09-27 BR BR112020005964-1A patent/BR112020005964A2/pt not_active Application Discontinuation
- 2018-09-27 CN CN201880076836.6A patent/CN111511743A/zh active Pending
-
2020
- 2020-03-27 US US16/832,067 patent/US11040974B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020535193A (ja) | 2020-12-03 |
| BR112020005964A2 (pt) | 2020-10-06 |
| WO2019064214A1 (en) | 2019-04-04 |
| KR20200092946A (ko) | 2020-08-04 |
| US11040974B2 (en) | 2021-06-22 |
| US20200354363A1 (en) | 2020-11-12 |
| CA3076980A1 (en) | 2019-04-04 |
| CN111511743A (zh) | 2020-08-07 |
| MX2020004050A (es) | 2020-11-06 |
| AU2018343236A1 (en) | 2020-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3964510T3 (fi) | Wee1-inhibiittoriyhdisteen kidemuoto ja sen käyttö | |
| JP2021530565A5 (cg-RX-API-DMAC7.html) | ||
| RU2017106602A (ru) | Способ получения (4s)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1-4-дигидро-1,6-нафтиридин-3-карбоксамида и его очистки для применения в качестве фармацевтического активного ингредиента | |
| RU2017102355A (ru) | Способ получения конденсированного гетероциклического соединения | |
| JP2015532645A5 (cg-RX-API-DMAC7.html) | ||
| JP2017222671A5 (cg-RX-API-DMAC7.html) | ||
| HRP20240695T1 (hr) | Novi polimorfi kalcijeve soli kao protuupalna, imunomodulatorna i anti-proliferacijska sredstva | |
| JP2019504103A5 (cg-RX-API-DMAC7.html) | ||
| RU2017134709A (ru) | П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения | |
| RU2021102393A (ru) | Твердые формы пладиенолидпиридиновых соединений и способы их применения | |
| CN104592183B (zh) | N-酰基-n-间氟苄基-8-氨基香豆素类化合物及其制备与除草用途 | |
| JP2018534243A5 (cg-RX-API-DMAC7.html) | ||
| CN111278820A (zh) | 一种吡啶酮化合物的晶型、盐型及其制备方法 | |
| RU2019118993A (ru) | Производное азациклобутилтриазола с конденсированной кольцевой группой, способ его получения и его применение в медицине | |
| JP2020535193A5 (cg-RX-API-DMAC7.html) | ||
| MX2024000326A (es) | Nuevas formas polimorficas de ciclo (-his-pro). | |
| JP2012515709A5 (cg-RX-API-DMAC7.html) | ||
| CN104829574A (zh) | 一种8-溴吡喃衍生物的制备方法 | |
| CN104829576A (zh) | 一种7-氟吡喃衍生物的制备方法 | |
| JP2018509421A5 (cg-RX-API-DMAC7.html) | ||
| EP2963007A1 (en) | Synthesis of Calebin-A and its biologically active analogs | |
| RU2015135184A (ru) | Способ получения соединения пиридазинона и промежуточных продуктов для его получения | |
| RU2019101109A (ru) | Твердые формы ингибитора ttk | |
| ZA202201469B (en) | Continuous process for preparing the crystalline form ii of sotagliflozin | |
| WO2017081702A2 (en) | A process for preparation of enzalutamide |